Cancer Center

Phone Numbers

Support Group Network
(803) 791-2800
Women's Imaging
(803) 791-2486
Lexington Radiation Oncology
(803) 791-2575
Lexington Oncology
(803) 794-7511

Lung Cancer

Our Lung Cancer Program

  • Lung cancer is the second most common cancer we diagnose.
  • Two national clinical trials for treatment based on genetic testing.
  • New, less-invasive TrueBeam™ radiation technology to treat lesions.

About 1 in 14 people in the United States has been diagnosed with lung cancer.

Treating Lung Cancer

Your lung cancer treatment will depend on the type and stage of your disease. Your doctor will discuss options with you and decide what's best for your individual diagnosis.

Other Possible Treatments

Nurse Navigators

A nurse navigator will work with you through the whole treatment process. She'll help you understand your diagnosis, take care of scheduling, and coordinate with doctors to get you the answers and help you need.

Supportive Care

Our care is comprehensive, with support for your personal challenges that goes beyond the disease itself.

Just a few ways we help:

New Treatments

We’ve been on the cutting edge of treatment for 20 years, and work to bring in new techniques for our patients.

Less-Invasive Radiation
With our new TrueBeam™ technology, we can treat lung lesions with fewer risks to patients, and a shorter recovery time.

Research Trials

We offer qualifying patients access to the latest clinical trials.

Enroll in a Clinical Trial

(803) 935-8300

Emerge 402

Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca

Open to enrollment

Posted By: Dr. Steven Madden

Posted Date: 11/1/2021

Location: Lexington Oncology

Alchemist - A151216

Genetic Testing For Patients with Resectable or Resected Lung Cancer

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial 

Open to enrollment 

Posted By: Dr. James Wells

Posted Date: 3/15/2015

Location: Lexington Oncology

Alchemist - E4512

Testing the Addition of the Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Open to enrollment 

Posted By: Dr. James Wells

Posted Date: 5/16/2016

Location: Lexington Oncology